- Home
- DSS vs BGLC Comparison
DSS vs BGLC Comparison
Compare DSS & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSS
- BGLC
- Stock Information
- Founded
- DSS 1984
- BGLC 2017
- Country
- DSS United States
- BGLC Malaysia
- Employees
- DSS N/A
- BGLC N/A
- Industry
- DSS Containers/Packaging
- BGLC Medical Specialities
- Sector
- DSS Consumer Discretionary
- BGLC Health Care
- Exchange
- DSS Nasdaq
- BGLC Nasdaq
- Market Cap
- DSS 7.3M
- BGLC 5.8M
- IPO Year
- DSS N/A
- BGLC N/A
- Fundamental
- Price
- DSS $0.87
- BGLC $0.28
- Analyst Decision
- DSS
- BGLC
- Analyst Count
- DSS 0
- BGLC 0
- Target Price
- DSS N/A
- BGLC N/A
- AVG Volume (30 Days)
- DSS 82.9K
- BGLC 1.5M
- Earning Date
- DSS 03-31-2025
- BGLC 05-14-2025
- Dividend Yield
- DSS N/A
- BGLC N/A
- EPS Growth
- DSS N/A
- BGLC N/A
- EPS
- DSS N/A
- BGLC N/A
- Revenue
- DSS $19,097,000.00
- BGLC $9,259,858.00
- Revenue This Year
- DSS N/A
- BGLC N/A
- Revenue Next Year
- DSS N/A
- BGLC N/A
- P/E Ratio
- DSS N/A
- BGLC N/A
- Revenue Growth
- DSS N/A
- BGLC N/A
- 52 Week Low
- DSS $0.77
- BGLC $0.21
- 52 Week High
- DSS $2.30
- BGLC $1.00
- Technical
- Relative Strength Index (RSI)
- DSS 43.96
- BGLC 28.87
- Support Level
- DSS $0.78
- BGLC $0.28
- Resistance Level
- DSS $1.03
- BGLC $0.32
- Average True Range (ATR)
- DSS 0.10
- BGLC 0.02
- MACD
- DSS -0.00
- BGLC -0.01
- Stochastic Oscillator
- DSS 25.97
- BGLC 6.44
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.